NEW
YORK, May 18, 2023 /PRNewswire/ -- Oramed
Pharmaceuticals Inc. (Nasdaq: ORMP) (TASE: ORMP) (www.oramed.com),
announced today that Chief Scientific Officer Dr. Miriam Kidron will deliver an in-person
presentation at the Novel Therapies for Type 2 Diabetes &
Obesity Summit in Boston, MA,
on May 31, 2023. The presentation
will include an overview of Oramed's oral delivery technology as
well as insights from the Company's recent Phase 3 oral insulin
clinical trials.
Presentation Details:
Novel Therapies for Type 2 Diabetes & Obesity
Summit
Date:
Wednesday, May 31, 2023
Time:
1:30 p.m. E.T.
Location: Hyatt
Regency Boston, Boston, MA
For more information regarding the summit and the presentation,
please visit the Summit's website: Home - Novel Therapies for Type
2 Diabetes & Obesity Summit 2023 (t2d-obesity-summit.com)
About Oramed Pharmaceuticals
Oramed Pharmaceuticals (Nasdaq/TASE: ORMP) is a platform
technology pioneer in the field of oral delivery solutions for
drugs currently delivered via injection. The Company's novel
Protein Oral Delivery (POD™) technology is designed to protect drug
integrity and increase absorption. Oramed has offices in
the United States and Israel. For more information, please
visit www.oramed.com.
Company Contact:
Zach Herschfus
+1-844-9-ORAMED
zach@oramed.com
Logo -
https://mma.prnewswire.com/media/1724339/Oramed_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/oramed-to-present-at-novel-therapies-for-type-2-diabetes--obesity-summit-301828322.html
SOURCE Oramed Pharmaceuticals Inc.